Targeted therapeuticts and their role in the treatment of internal diseases

Česká verzia

Authors: P. Klener
Authors place of work: I. interní klinika 1. lékařské fakulty UK a VFN a ÚHKT Praha, přednosta prof. MUDr. Marek Trněný, CSc.
Published in the journal: Vnitř Lék 2013; 59(1): 5-12
Category: Celebratory Discourse

Předneseno jako slavnostní přednáška na zahájení XIX. kongresu České internistické společnosti České lékařské společnosti J. E. Purkyně v Brně dne 24. října 2012.

Summary

Targeted therapy is a conceptual notion that should be used for such a treatment approach that has been developed based upon the known pathophysiology and/or biomarkers of a particular disease, mainly malignancies. Monoclonal antibodies and tyrosine--kinase inhibitors were among the first molecularly targeted agents. Monoclonal antibodies approach is based on targeting a biomarker expressed either on the surface of cancer cells or targeting different cytokines. Tyrosin-kinase inhibitors are directed at the druggable molecule involved in the cancer pathophysiology inhibiting aberrant tyrosin-kinase activity. Classification of targeted drugs and their use in the clinical practice is shortly reviewed.

Key words:
targeted therapy – monoclonal antibodies – tyrosin-kinase inhibitors – classification – clinical use

Zdroje

1. Airley R. Cancer chemotherapy. Willey-Blackwell, Oxford 2009.

2. Dorr RT, Von Hoff DD. Cancer chemotherapy handbook. Appleton and Lange, Norwalk, 1994.

3. Klener P. Klinická onkologie.Praha: Galén-Karolinum 2002.

4. Mladosievičová B et al. Molekulové mechanizmy patogenézy nádorov. Bratislava: SAP 2011, 123 s.

5. Estey E. New drugs in acute myeloid leukemia. Semin Oncol 2008; 35: 439–448.

6. Mayer J, Klamová H, Žáčková D et al. Imatinib v první linii léčby s nově diagnostikovanou chronickou myeloidní leukemií v chronické fázi. Transfuze Hematol Dnes 2008; 15: 150–158.

7. Klener P, Klener jr. P. Nová protinádorová léčiva a léčebné strategie v onkologii. Praha: Grada Publishingh 2010.

8. Moreira IS, Fernandes PA, Ramos MJ. Vascular endothelial growth fractor (VEGF) inhibition - a critical review. Anticancer agents Med Chem 2007; 7:223–245.

9. Hartman JT, Haap M, Koop HG et al. Tyrosine kinase inhibitors – a review on pharmacology metabolism and side effects. Curr Drug Metab 2009; 10: 470–481.

10. Wong MK, Lo AL, Lam B et al. Erlotinib as a salvage treatment after failure of first line gefitinib in non small cell lung cancer. Cancer Chemother Pharmacol 2009; 64: 656–663.

11. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005; 438: 967–974.

12. Chan S. Targeting the mammalian target of rapamycin (m-TOR): a new approach to treating cancer. Br J Cancer 2004; 25: 1420–1424.

13. Klener P, Klener jr. P. ABL1, SRC a další nereceptorové proteinkinázy jako nové cíle specifické protinádorové terapie. Klin Onkol 2010; 23: 203–209.

14. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nature Biotechnol 2005; 23: 1147–1157.

15. Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Natur Rev 2010; 10: 317–327.

16. Belada D. Monoklonální protilátky v léčbě lymfomů. Remedia 2008; 6: 416–423.

17. Tazi L, Nafil H, Mahmal L. Monoclonal antibodies in hematological malignancies: past, present and future. J Cancer Res Ther 2012; 7: 309–407.

18. Castillo J, Winer E, Quinsberry O. Newer monoclonal antibodies for hematological malignancies. Exp Hematol 2008; 36: 755–768.

19. Palácová M. Trastuzumab. Remedia 2009; 20: 4–13.

20. Van Cutsem E. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. New Engl J Med 2009; 369: 1408–1417.

21. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of antitumor activity. Cancer 2008; 8: 579–591.

22. Weber J. Ipilimumab: controversies in its development, utility and autoimmune adverse events. Cancer Immunol Immunother 2009; 58: 823–830.

23. Chan AC, Carter PJ. Therapeutic antibodies for autoimmunity and inflammation. Nature rev 2010; 10: 301–316.

24. Choy EHS, Kingsley GH, Panayi GS. Monoclonal antibody therapy in rheumatoid arthritis. Brit J Rhematol 1998; 37: 484–490.

25. Yuvienco C, Schwartz S. Monoclonal antibodies in rheumatic diseases. Med Health/Rhode Island 2011; 94: 320–324.

26. Hanauer SB, Sandborn WJ, Rutgeerts P et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn´s disease. Gastroenteology 2006; 130: 323–333.

27. Kelly RJ, Hill A, Arnold LM et al. Long-term treatment with eculimumab in paroxaysmal nocturnal hemoglobinuria. Blood 2011; 117: 6786–6792.

28. Polman CH, O´Connor PW, Havrdova E et al. A randomized, placebo controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899–904.

29. Carter PJ, Senter PD. Antibody-drug conjugates for cancer therapy. Cancer J 2008; 14: 154–169.

30. Kontermann RF. Recombinant bispecific antibodies for cancer. Acta Pharmacol 2005; 26: 1–9.

31. Goldenberg DM, Cardillo IM, Shi V et al. Bispecific anti CD20/22 antibodies inhibit B-cell lymphoma proliferation by unique mechanism of action. Blood 2008; 111: 2211–2219.

32. Nelson AI, Reichert JM. Development trends for therapeutic antibody fragments. Nature Biotechnol 2009; 27: 331–337.